Recurrent Platinum-Resistant Ovarian Carcinoma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Recurrent Platinum-Resistant Ovarian Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239
Recruiting
Phase 1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 1

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)60 enrolled14 locationsNCT05950464
Recruiting
Phase 1

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting
Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Phase 1

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Ovarian CancerOvarian CarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
Elizabeth Stover, MD, PhD30 enrolled3 locationsNCT06964009